compounded semaglutide and glycine Semaglutide/Glycine/B12 for at Home Use Semaglutide glycine B12 blend: complete

Breaking through weight loss plateaus

Dual GIP/GLP-1 agonists add GIP receptor activation, which: Amplifies insulin secretion beyond what GLP-1 alone achieves Increases insulin sensitivity in peripheral tissues Appears to shift adipocyte metabolism toward fat oxidation (mechanism still under investigation) May reduce the nausea signal that limits GLP-1 dose escalation (GIP has anti-emetic properties in animal models) The weight loss ceiling for tirzepatide is approximately 20% to 22% of baseline body weight at the 15 mg dose over 72 weeks (SURMOUNT-1 data)

Microdosing The microdosing approach uses much lower amounts, often 0.5 to 1.5 mg per dose, for specific applications like inflammation management

Our program uses food, sleep, movement, and coaching

This makes it an ideal complement to Supresa in the Lemme GLP-1 formula, creating a comprehensive approach to metabolic support and weight management